Tina Sajadi
Primary Care · Las Vegas, NVNPI 1952061202
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 75 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 23.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,345 and has fallen 78.8% since, to $285 in 2025.
Across 75 payments — averaging $22.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$389
- AstraZeneca$326
- AbbVie$221
- Bayer$199
- Amgen$152
- Vanda Pharmaceuticals Inc.$76
- plus $290 from 8 others
What the payments were for
- Food & beverage$1,654100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 21 | $389 |
| AstraZeneca | 7 | $326 |
| AbbVie | 16 | $221 |
| Bayer | 9 | $199 |
| Amgen | 6 | $152 |
| Vanda Pharmaceuticals Inc. | 3 | $76 |
| Pfizer | 3 | $57 |
| Lilly USA, LLC | 3 | $54 |
| Hologic Sales And Service, LLC | 1 | $50 |
| Astellas Pharma US Inc | 2 | $46 |
| Corium, LLC | 1 | $33 |
| Idorsia Pharmaceuticals US Inc | 1 | $21 |
| Dexcom, Inc. | 1 | $15 |
| Phadia US Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,654 in reported general payments places this provider in the 80th percentile of 81 primary care providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Venlafaxine Hcl ErVenlafaxine Hcl | 13 | $498 |
| Quetiapine Fumarate | 40 | $255 |
| Bupropion XlBupropion Hcl | 17 | $196 |
| Fluoxetine Hcl | 22 | $170 |
| Mirtazapine | 12 | $156 |
| Atorvastatin Calcium | 13 | $145 |
| Escitalopram Oxalate | 19 | $139 |
| Trazodone Hcl | 19 | $78 |
| Sertraline Hcl | 29 | $66 |
| Alprazolam | 16 | $47 |
| Lisinopril | 11 | $41 |
| Buspirone Hcl | 14 | $39 |
| Clonazepam | 14 | $18 |
Paid to pharmacies, not to this prescriber.
Other primary care in Las Vegas
- Jennifer CribbLas Vegas$7K
- Ruel MarianoLas Vegas$4K
- George Gabriel ToldnessLas Vegas$4K
- Jona SteadLas Vegas$3K
- Mario LuglioLas Vegas$3K
- Jocybel ItorralbaLas Vegas$3K
- Jerifaye FloresLas Vegas$2K
- Sneha ThomasLas Vegas$2K
- Yoslady MoralesLas Vegas$2K
- Christine EspenillaLas Vegas$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.